Sfoglia per Corso
A retrospective, real-world experience with adjuvant abemaciclib in high-risk HR+/HER2− early breast cancer: tolerability, dose modifications, and outcomes.
2024/2025 NAPETTI, DAVIDE
ageUVANT: Evaluation of heterogeneity in neoadjuvant and adjuvant therapy prescription in elderly and/or comorbid patients with melanoma
2023/2024 PORRA, FRANCESCA
Assessment of PD-L1 on matched surgical specimen and biopsy in resectable esophagogastric cancer: The APEROL multicentric study
2023/2024 RICAGNO, GIANMARCO
Clinical and molecular predictors of outcome after first-line Osimertinib in EGFR-mutated Non-small cell lung cancer
2024/2025 PANTE, FRANCESCA
Clinical, molecular and metabolic assessment in vorasidenib-treated IDH-mutant gliomas: the VORAFET study
2024/2025 BOSIO, ALBERTO
Clinically actionable genomic alterations in breast cancer brain metastases: A Multi-Institutional Retrospective Study
2022/2023 GUARASCIO, MARIA CRISTINA
Concordanza tra stadio clinico e patologico in pazienti con carcinoma mammario triplo negativo sottoposte a chirurgia upfront
2023/2024 MARINO, MONICA
Evolving treatment strategies in early-stage and locally advanced non-small cell lung cancer: the impact of neoadjuvant chemo-immunotherapy in the real world
2024/2025 SANGIORGI, SARA
Hepatocellular carcinoma with macrovascular invasion: review and survival meta-analysis of initial local therapy using minimal prognostic criteria
2023/2024 DE ROSA, ANTONIO
Immune and Gene-expression Profiling in Estrogen Receptor Low and Negative Early Breast Cancer
2022/2023 MASSA, DAVIDE
Impact of timing of neoadjuvant pembrolizumab infusion on pathological response in patients treated with the KEYNOTE-522 regimen: a single-centre retrospective study.
2024/2025 BONOMI, GIORGIO
Modern Therapeutic Strategies in Anaplastic Thyroid Carcinoma: Real-World Outcomes of Targeted Therapy and Immunotherapy
2023/2024 MICHELETTO, ILARIA
Oxaliplatin- and temozolomide-based therapy in metastatic GEP-NETs: a monocentric comparison.
2023/2024 CERANTOLA, RICCARDO
PAXG vs FOLFIRINOX: Comparative Clinical Outcomes of Intensive Polychemotherapy Regimens as First-Line Treatment for Metastatic Pancreatic Cancer
2024/2025 DI PAOLO, GIACOMO
Profilo mutazionale su ctDNA ed outcome clinico nel carcinoma mammario HR+/HER2- avanzato: analisi di PIK3CA/AKT/PTEN ed ESR1 nello studio CHAMBER
2024/2025 ZANGHÌ, FRANCESCA
Prognostic and predictive impact of HER2 expression in metastatic urothelial carcinoma: results from the single-center BladdHER study.
2023/2024 ERBETTA, ELISA
Radiomic approach to support Multidisciplinary Tumor Board decision-making in Locally Advanced Non-Small Cell Lung Cancer
2023/2024 DE NUZZO, MATTIA
Real-World outcomes of Darolutamide + docetaxel + androgen deprivation therapy combination in patients with metastatIc castration sensitive prostate cancer within the Italian multicenter observational study (ECHOS trial)
2022/2023 CAVASIN, NICOLÒ
RetrOspective study of anDrogen rEceptor expressiOn in clear cell renal carcinoma (RODEO)
2024/2025 PITTARELLO, CHIARA
Role of sidedness in pMMR/MSS BRAF mutated metastatic colorectal cancer: descriptive and prognostic analyses from a large real-world clinical cohort
2023/2024 PERISSINOTTO, ELEONORA
| Tipologia | Anno | Titolo | Titolo inglese | Autore | File |
|---|---|---|---|---|---|
| Scuole di Specializzazione | 2024 | A retrospective, real-world experience with adjuvant abemaciclib in high-risk HR+/HER2− early breast cancer: tolerability, dose modifications, and outcomes. | A retrospective, real-world experience with adjuvant abemaciclib in high-risk HR+/HER2− early breast cancer: tolerability, dose modifications, and outcomes. | NAPETTI, DAVIDE | |
| Scuole di Specializzazione | 2023 | ageUVANT: Evaluation of heterogeneity in neoadjuvant and adjuvant therapy prescription in elderly and/or comorbid patients with melanoma | ageUVANT: Evaluation of heterogeneity in neoadjuvant and adjuvant therapy prescription in elderly and/or comorbid patients with melanoma | PORRA, FRANCESCA | |
| Scuole di Specializzazione | 2023 | Assessment of PD-L1 on matched surgical specimen and biopsy in resectable esophagogastric cancer: The APEROL multicentric study | Assessment of PD-L1 on matched surgical specimen and biopsy in resectable esophagogastric cancer: The APEROL multicentric study | RICAGNO, GIANMARCO | |
| Scuole di Specializzazione | 2024 | Clinical and molecular predictors of outcome after first-line Osimertinib in EGFR-mutated Non-small cell lung cancer | Clinical and molecular predictors of outcome after first-line Osimertinib in EGFR-mutated Non-small cell lung ancer | PANTE, FRANCESCA | |
| Scuole di Specializzazione | 2024 | Clinical, molecular and metabolic assessment in vorasidenib-treated IDH-mutant gliomas: the VORAFET study | Clinical, molecular and metabolic assessment in vorasidenib-treated IDH-mutant gliomas: the VORAFET study | BOSIO, ALBERTO | |
| Scuole di Specializzazione | 2022 | Clinically actionable genomic alterations in breast cancer brain metastases: A Multi-Institutional Retrospective Study | Clinically actionable genomic alterations in breast cancer brain metastases: A Multi-Institutional Retrospective Study | GUARASCIO, MARIA CRISTINA | |
| Scuole di Specializzazione | 2023 | Concordanza tra stadio clinico e patologico in pazienti con carcinoma mammario triplo negativo sottoposte a chirurgia upfront | Concordance between clinical and pathological staging in patients with triple negative breast cancer undergoing upfront surgery | MARINO, MONICA | |
| Scuole di Specializzazione | 2024 | Evolving treatment strategies in early-stage and locally advanced non-small cell lung cancer: the impact of neoadjuvant chemo-immunotherapy in the real world | Evolving treatment strategies in early-stage and locally advanced non-small cell lung cancer: the impact of neoadjuvant chemo-immunotherapy in the real world | SANGIORGI, SARA | |
| Scuole di Specializzazione | 2023 | Hepatocellular carcinoma with macrovascular invasion: review and survival meta-analysis of initial local therapy using minimal prognostic criteria | Hepatocellular carcinoma with macrovascular invasion: review and survival meta-analysis of initial local therapy using minimal prognostic criteria | DE ROSA, ANTONIO | |
| Scuole di Specializzazione | 2022 | Immune and Gene-expression Profiling in Estrogen Receptor Low and Negative Early Breast Cancer | Immune and Gene-expression Profiling in Estrogen Receptor Low and Negative Early Breast Cancer | MASSA, DAVIDE | |
| Scuole di Specializzazione | 2024 | Impact of timing of neoadjuvant pembrolizumab infusion on pathological response in patients treated with the KEYNOTE-522 regimen: a single-centre retrospective study. | Impact of timing of neoadjuvant pembrolizumab infusion on pathological response in patients treated with the KEYNOTE-522 regimen: a single-centre retrospective study. | BONOMI, GIORGIO | |
| Scuole di Specializzazione | 2023 | Modern Therapeutic Strategies in Anaplastic Thyroid Carcinoma: Real-World Outcomes of Targeted Therapy and Immunotherapy | Modern Therapeutic Strategies in Anaplastic Thyroid Carcinoma: Real-World Outcomes of Targeted Therapy and Immunotherapy | MICHELETTO, ILARIA | |
| Scuole di Specializzazione | 2023 | Oxaliplatin- and temozolomide-based therapy in metastatic GEP-NETs: a monocentric comparison. | Oxaliplatin- and temozolomide-based therapy in metastatic GEP-NETs: a monocentric comparison. | CERANTOLA, RICCARDO | |
| Scuole di Specializzazione | 2024 | PAXG vs FOLFIRINOX: Comparative Clinical Outcomes of Intensive Polychemotherapy Regimens as First-Line Treatment for Metastatic Pancreatic Cancer | PAXG vs FOLFIRINOX: Comparative Clinical Outcomes of Intensive Polychemotherapy Regimens as First-Line Treatment for Metastatic Pancreatic Cancer | DI PAOLO, GIACOMO | |
| Scuole di Specializzazione | 2024 | Profilo mutazionale su ctDNA ed outcome clinico nel carcinoma mammario HR+/HER2- avanzato: analisi di PIK3CA/AKT/PTEN ed ESR1 nello studio CHAMBER | Mutational profile of ctDNA and clinical outcomes in advanced HR+/HER2− breast cancer: analysis of PIK3CA/AKT/PTEN and ESR1 in the CHAMBER Study | ZANGHÌ, FRANCESCA | |
| Scuole di Specializzazione | 2023 | Prognostic and predictive impact of HER2 expression in metastatic urothelial carcinoma: results from the single-center BladdHER study. | Prognostic and predictive impact of HER2 expression in metastatic urothelial carcinoma: results from the single-center BladdHER study. | ERBETTA, ELISA | |
| Scuole di Specializzazione | 2023 | Radiomic approach to support Multidisciplinary Tumor Board decision-making in Locally Advanced Non-Small Cell Lung Cancer | Radiomic approach to support Multidisciplinary Tumor Board decision-making in Locally Advanced Non-Small Cell Lung Cancer | DE NUZZO, MATTIA | |
| Scuole di Specializzazione | 2022 | Real-World outcomes of Darolutamide + docetaxel + androgen deprivation therapy combination in patients with metastatIc castration sensitive prostate cancer within the Italian multicenter observational study (ECHOS trial) | Real-World outcomes of Darolutamide + docetaxel + androgen deprivation therapy combination in patients with metastatIc castration sensitive prostate cancer within the Italian multicenter observational study (ECHOS trial) | CAVASIN, NICOLÒ | |
| Scuole di Specializzazione | 2024 | RetrOspective study of anDrogen rEceptor expressiOn in clear cell renal carcinoma (RODEO) | RetrOspective study of anDrogen rEceptor expressiOn in clear cell renal carcinoma (RODEO) | PITTARELLO, CHIARA | |
| Scuole di Specializzazione | 2023 | Role of sidedness in pMMR/MSS BRAF mutated metastatic colorectal cancer: descriptive and prognostic analyses from a large real-world clinical cohort | Role of sidedness in pMMR/MSS BRAF mutated metastatic colorectal cancer: descriptive and prognostic analyses from a large real-world clinical cohort | PERISSINOTTO, ELEONORA |
Legenda icone
- file ad accesso aperto
- file ad accesso riservato
- file sotto embargo
- nessun file disponibile